The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Meet revised 2022 World Health Organization (WHO) and 2022 International Consensus Classification criteria for the diagnosis of PV.
2. Participants must be phlebotomy-dependent.
3. Hct less than (\<) 45% at study start.
4. Participants receiving Cytoreduction therapy (CRT) must be on a stable regimen at study start.
5. Adequate organ function and electrolytes.
Exclusion Criteria:
1. Prior treatment of PV with Transmembrane serine protease 6 (TMPRSS6) inhibitors, including sapablursen, or hepcidin mimetics.
2. Clinically significant thrombosis (eg, myocardial infarction, stroke, deep vein thrombosis or splenic vein thrombosis) within 1 month prior to randomization.
3. Participants who require phlebotomy at Hct levels \<45%.
4. Meet the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment.
5. Any serious or unstable medical condition or uncontrolled psychiatric condition that would interfere with their ability to comply with study requirements.
Primary outcome measure(s)
Percentage of Participants with Absence of Phlebotomy Eligibility — Week 20 through Week 32 Response is defined as absence of phlebotomy eligibility.
Trial sites (10)
Facility
City
Region
Status
Regis Clinical Research LLC.
Miami
Florida
Recruiting
Florida Clinical Trials Group
Plantation
Florida
Recruiting
Florida Clinical Trials Group
Tamarac
Florida
Recruiting
Central Georgia Cancer Care
Macon
Georgia
Recruiting
The Center for Cancer & Blood Disorders
Bethesda
Maryland
Recruiting
The Cancer and Hematology Centers
Grand Rapids
Michigan
Recruiting
Montefiore Medical Center
The Bronx
New York
Recruiting
Gabrail Cancer Center Research
Canton
Ohio
Recruiting
Perth Blood Institute
West Perth
Western Australia
Recruiting
Japanese Red Cross Nagasaki Genbaku Hospital
Nagasaki
Japan
Recruiting
More Ono Pharmaceutical Co., Ltd. trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.